Showing results (51-60 of 57) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Cancer Biology & Therapy|December 2, 2011
New variants at 10q26 and 15q21 are associated with aggressive prostate cancer in a genome-wide association study from a prostate biopsy screening cohortRobert K Nam, William Zhang, Katherine Siminovitch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2004
American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancerD Andrew Loblaw, David S Mendelson, James A Talcott, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2018
Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology GuidelineJustin E Bekelman, R Bryan Rumble, Ronald C Chen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2014
Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guidelineEthan Basch, D Andrew Loblaw, Thomas K Oliver, et al.Advances in Radiation Oncology|June 13, 2020
Gantry-Mounted Linear Accelerator-Based Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate CancerAudrey T Dang, Rebecca G Levin-Epstein, David Shabsovich, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 14, 2021
Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyondTing Martin Ma, Soumyajit Roy, Xue Wu, et al.JAMA Network Open|February 9, 2019
Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate CancerAmar U Kishan, Audrey Dang, Alan J Katz, et al.Pageof 6